Moreover, the chromatin modification in the ERα promoter region predicted melanoma progression and the reactivation of this gene made tumor cells sensitive to antiestrogens (that normally cannot be used to treat patients affected also by colorectal cancer, lung cancer, and melanoma in which the ERα promoter region is methylated). This evidence concerns the gene ESR1 and neoplasm.